AzTrials
AzTrials

Parkinson DiseaseNCT04620863

TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE

A study testing t-DCS group in people with Parkinson Disease and Pisa Syndrome, run by IRCCS National Neurological Institute "C. Mondino" Foundation at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Pisa Syndrome (PS) is a lateral trunk flexion frequently associated to Parkinson's disease (PD). The management of PS is still a challenge for the clinician, because it poorly responds to anti-parkinsonian drugs, and the improvement achieved with neurorehabilitation or botulinum toxin injections tends to fade in 6… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Parkinson Disease, Pisa Syndrome
What is being tested?
t-DCS group
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
30 participants
Where
1 siteItaly
Study dates
15 Jan 2019to 15 Sep 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age between 18 and 80 years;
  • Hoehn and Yahr stage between II and III;
  • Mini-Mental State Examination score above 24;
  • lateral trunk flexion of at least 10° at baseline.

Who cannot join

  • history of major psychiatric or other neurological conditions;
  • history of back surgery, tumors or infections of the spine, intradural or extradural hematoma, ankylosing spondylitis, spinal stenosis;
  • history of idiopathic scoliosis;
  • botulin toxin treatment in the previous year;
  • any change in dose or regimen of the anti-parkinsonian therapy in the last month before enrolment.
  • Thirty patients affected by Parkinson' Disease (PD) and Pisa Syndrome (PS) were consecutive enrolled among those attending the Neurorehabilitation Department of the IRCCS Mondino Foundation (Pavia, Italy). Idiopathic PD was diagnosed according to the Movement Disorders Society clinical diagnostic criteria for PD. Pisa syndrome was clinically diagnosed according to the following criteria:
Show all 10Show fewer
  • a lateral flexion of the trunk with a homogenous angle between sacrum and spinous process of the 7th cervical vertebra;
  • an ipsilateral axial rotation of the trunk around the sagittal axis, that leads to a higher and anterior position of the shoulder contralateral to the side of trunk deviation;
  • the worsening of the postural disorder during standing position, sitting position and gait;
  • the improvement of the postural disorder in supine position.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Neurorehabilitation Department

    Pavia, 27100

Other trials in Italy

About this study

Official title: TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL

Pisa Syndrome (PS) is a lateral trunk flexion frequently associated to Parkinson's disease (PD). The management of PS is still a challenge for the clinician, because it poorly responds to anti-parkinsonian drugs, and the improvement achieved with neurorehabilitation or botulinum toxin injections tends to fade in 6 months or less. Transcranial direct current stimulation (t-DCS) is a non-invasive neuromodulation technique, with promising results in movement disorders. Aim of our study is to evaluate the role of bi-hemispheric t-DCS as add-on to neurorehabilitation in PS. Twenty-eight patients affected by PD and PS were managed with a 4-week hospital neurorehabilitation programme and randomized to: 1) t-DCS group: 5 daily sessions (20 minutes - 2 mA) with cathode over the primary motor cortex (M1) contralateral to PS, and anode over the M1 cortex ipsilateral to PS; or 2) sham group. Patients were tested with kinematic analysis of trunk movement in static and dynamic conditions, UPDRS-III, FIM, and VAS for lumbar pain rating at hospital admission (T0), at hospital discharge (end of neurorehabilitation - T1), and 6 months later (T2). At T0, the evaluations were completed by an EMG study of trunk muscles activation.

Read the detailed description

Axial disorders are frequent complications of Parkinson's Disease (PD) and they can lead to postural deformities and balance impairments. The most prevalent postural disorders of PD are represented by camptocormia, antecollis, scoliosis, and Pisa syndrome (PS).

The pathogenesis of these disorders has not yet been completely elucidated, and it is characterized by a complex interlacement between central and peripheral mechanisms.

The first report of PS dates back in 1972, when Ekobm described a case series of three patients who developed a lateral trunk flexion in close temporal relationship with neuroleptics assumption. The roster of drugs associated with an acute/subacute onset of PS is huge and constantly growing, and it includes: antidepressants (mirtazapine, sertraline), cholinesterase inhibitor (rivastigmine, galantamine, donepezil), neuroleptics (tiapride, clotiapine, clozapine, aipiprazole, butyrophenone, paliperidone, quetiapine), dopamine agonists, (pramipexolo, ropinirole, pergolide), lithium, valproic acid, and betahistine. Nonetheless, PS was described as well in patients with neurodegenerative disorders, and in particular in PD and parkinsonism without drugs exposure.

The prevalence of PS is around 8.3% (9.3% in women and 6.4% in men) when calculated in a psychogeriatric population, and it is 8 to 8.8% when populations of PD patients were considered.

Formal diagnostic criteria for PS are not available, indeed the diagnosis is based on the clinical features:

  • presence of a lateral flexion of the trunk with a homogenous angle between sacrum and spinous process of the 7th cervical vertebra;
  • association of an ipsilateral rotation of the trunk around the sagittal axis that leads to a higher and anterior position of the shoulder contralateral to the side of trunk deviation;
  • the postural disorder worsens during standing position, sitting position and gait;
  • the postural disorder improves in supine position;
  • disregard of patients for the postural disorder.

The fluctuation of the postural alteration during static (supine position vs. upright standing position) and dynamic conditions appears to be crucial to differentiate PS from scoliosis.

A lateral trunk deviation of at least 10° is commonly accepted for the diagnosis, although higher or lower cut-offs were used in the past. According to the degree of the lateral trunk flexion, PS can be further divided in mild (less than 20°) or severe (more than 20°) phenotypes.

Patients with PD and PS showed some typical clinical and demographic features when compared to PD patients without postural alterations: they are older, PD is longer in duration, more severe and with a more pronounced asymmetry of motor symptoms. The parkinsonian symptoms involving the upper limbs as well as gait impairment are more severe in PD patients with PS. Moreover, they are characterized by a higher incidence of falls, arthrosis, osteoporosis, orthopedics diseases and pain, specifically lumbar and lower back pain, which is reported in up to 75% of patients with PD and PS.

The management of PS is still a challenge for the physician. PS poorly responds to antiparkinsonian drugs, although there aren't studies specifically designed to assess this topic.

Neurorehabilitation represents one of the fundamental approach to PD and to postural disorders in general, not only for the treatment of the motor symptoms itself but also to improve quality of life and autonomy in the activity of daily living.

The study was a randomized, double-blind, controlled trial aimed to assess the efficacy of five daily sessions of bi-hemispheric t-DCS in add-on to an in-hospital neurorehabilitation protocol in patients affected by PD and PS.

At hospital admission (T0 - baseline), all patients underwent complete neurological, general and functional examinations by a Neurologist with expertise in movement disorders and neurorehabilitation. Patients who fulfilled inclusion and exclusion criteria underwent a baseline kinematic analysis of trunk movement. Patients with at least 10° of lateral trunk flexion completed the baseline evaluations with a dynamic electromyographic (EMG) study of trunk muscles, and with administration of a set clinical scales for the evaluations of motor disability, functional independence, and lumbar pain.

After that, patients were randomly assigned to "t-DCS" or "sham" treatment, and they started the double-blind phase of the study. The 5-day t-DCS/sham treatment was delivered in 5 daily consecutive sessions, starting from the first Monday after hospital admission. In parallel to neuromodulation, all patients were treated with a standardized 4-week rehabilitation programme. The kinematic analysis of trunk movement as well as the administration of the set of questionnaires were repeated at the end of the 4-week rehabilitation programme (T1 - hospital discharge), and 6 months after discharge (T2).

The randomization was performed according to a block randomization method. A unique randomization list was generated before enrollment with the following parameters: 6 blocks; 6 patients per block (3 for t-DCS group, and 3 for sham group).

All the patients were treated with an optimized and individualized anti-parkinsonian therapy, which dose and regimen were kept stable during the overall study period. All the evaluations were performed in the morning, and always in an ON phase.

The specific and standardized in-hospital rehabilitation programme was focused on the rehabilitation of the trunk postural disorder. All patients were treated with 90-minute daily sessions, 6 days a week (Monday to Saturday) for four weeks.

Each session was structured as follow:

  • 10 minutes of cardiovascular warm-up activities: intersegmental coordination exercises; exercises to release shoulder and pelvic girdle; pelvic anteversion and retroversion movements to improve diaphragmatic respiration (supine position); breathing exercises to promote expansion of the chest;
  • 15 minutes of stretching exercises: exercises to stretch the muscles of the posterior kinematic chain; exercises to stretch the pectoralis muscles; exercises to stretch the ischio-cruralis muscles; assumption of the prone position, sitting on heels and stretching the arms out in front; the "bridge" exercise to stretch the muscles of the anterior abdominal wall, glutei, quadriceps and hamstring; exercises to stretch lumbar muscles (in the supine position, each knee, in turn, is brought to the chest);
  • 15 minutes of strengthening exercises in a functional context: exercises to strengthen the dorsal muscles (arms extended and hands outstretched as though to take something); lateral bending (arms lying along the body and hands reaching down as though to pick up something); stretching using the wall bars;
  • 20 minutes of gait training: overground gait training (forwards, backwards, and lateral); walking on the spot;
  • 15 minutes of balance training: path with obstacles; balance exercises performed in order of difficulty (heel-to-toe walking, lateral walking crossing the legs, walking along a path on surfaces of different texture);
  • 15 minutes of relaxation exercises: intersegmental coordination exercises; segmental passive mobilization (until maximum joint range of motion is reached); breathing exercises to promote expansion of the chest.
Being tested
t-DCS group, Sham group
Keywords
Parkinson Disease, Pisa Syndrome, Transcranial direct current stimulation
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • t-DCS groupOther

    All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).

  • Sham groupOther

    The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.

Study groups in NCT04620863
Study groupRoleWhat they receive
tDCS groupExperimentalPatients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
Receives: Other: t-DCS group
Sham GroupSham comparatorThe stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
Receives: Other: Sham group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of Stat Tot (Stat Bend + Stat Flex)

    Total postural alteration in the upright standing position (Stat Tot): lateral trunk inclination in the upright standing position (Stat Bend) plus anterior trunk flexion in the upright standing position (Stat Flex).

    Measured: Change from Baseline at 28 weeks (T2)

Secondary outcomes (10)
  1. Change of Stat Bend

    Lateral trunk inclination in the upright standing position

    Measured: Change from Baseline at 28 weeks (T2)

  2. Change of Stat Flex

    Anterior trunk flexion in the upright standing position

    Measured: Change from Baseline at 28 weeks (T2)

  3. Change of ROM Ips

    Range of Motion (ROM) of trunk bending ipsilateral to the side of trunk deviation

    Measured: Change from Baseline at 28 weeks (T2)

  4. Change of ROM Con

    Range of Motion (ROM) of trunk bending contralateral to the side of trunk deviation

    Measured: Change from Baseline at 28 weeks (T2)

  5. Change of ROM flex

    Range of Motion (ROM) of anterior trunk flexion

    Measured: Change from Baseline at 28 weeks (T2)

  6. Change of ROM Ext

    Range of Motion (ROM) of posterior trunk extension

    Measured: Change from Baseline at 28 weeks (T2)

  7. Change of Total ROM of the trunk

    ROM Ips + ROM Con + ROM Flex + ROM Ext

    Measured: Change from Baseline at 28 weeks (T2)

  8. Change of The Unified Parkinson's Disease Rating Scale - part III - Motor examination (UPDRS-III)

    It consists of 18 items (score from 0 to 4). Higher scores are worst otcomes.

    Measured: Change from Baseline at 28 weeks (T2)

  9. Change of Functional Independence Measure (FIM)

    The Functional Independence Measure (FIM) is an 18-item measurement tool that explores an individual's physical, psychological and social function. FIM scores range from 1 to 7 (1= total assist and 7= complete independence).

    Measured: Change from Baseline at 28 weeks (T2)

  10. Change of Visual analog scale (VAS).

    Lumbar pain severity was rated according to a 0 to 10 visual analog scale. Zero is no pain and 10 is worst pain.

    Measured: Change from Baseline at 28 weeks (T2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2020
  2. Study start15 Jan 2019
  3. Primary completion15 Aug 2020
  4. Study completion15 Sep 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study was a randomized, double-blind, controlled trial
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04620863
Sponsor's protocol ID
Pisa-tDCS
Status last verified
Oct 2020
First submitted
26 Oct 2020
Last updated
13 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972;202(2):94-103. doi: 10.1007/BF00316159. No abstract available.

    PubMed 4115928
  • Gambarin M, Antonini A, Moretto G, Bovi P, Romito S, Fiaschi A, Tinazzi M. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. Mov Disord. 2006 Feb;21(2):270-3. doi: 10.1002/mds.20711.

    PubMed 16161148
  • Barone P, Santangelo G, Amboni M, Pellecchia MT, Vitale C. Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. Lancet Neurol. 2016 Sep;15(10):1063-74. doi: 10.1016/S1474-4422(16)30173-9. Epub 2016 Aug 8.

    PubMed 27571158
  • Tinazzi M, Gandolfi M, Ceravolo R, Capecci M, Andrenelli E, Ceravolo MG, Bonanni L, Onofrj M, Vitale M, Catalan M, Polverino P, Bertolotti C, Mazzucchi S, Giannoni S, Smania N, Tamburin S, Vacca L, Stocchi F, Radicati FG, Artusi CA, Zibetti M, Lopiano L, Fasano A, Geroin C. Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. Mov Disord Clin Pract. 2019 Jun 29;6(7):576-585. doi: 10.1002/mdc3.12810. eCollection 2019 Sep.

    PubMed 31538092
  • Tinazzi M, Fasano A, Geroin C, Morgante F, Ceravolo R, Rossi S, Thomas A, Fabbrini G, Bentivoglio A, Tamma F, Cossu G, Modugno N, Zappia M, Volonte MA, Dallocchio C, Abbruzzese G, Pacchetti C, Marconi R, Defazio G, Canesi M, Cannas A, Pisani A, Mirandola R, Barone P, Vitale C; Italian Pisa Syndrome Study Group. Pisa syndrome in Parkinson disease: An observational multicenter Italian study. Neurology. 2015 Nov 17;85(20):1769-79. doi: 10.1212/WNL.0000000000002122. Epub 2015 Oct 21.

    PubMed 26491088
  • Tassorelli C, Furnari A, Buscone S, Alfonsi E, Pacchetti C, Zangaglia R, Pichiecchio A, Bastianello S, Lozza A, Allena M, Bolla M, Sandrini G, Nappi G, Martignoni E. Pisa syndrome in Parkinson's disease: clinical, electromyographic, and radiological characterization. Mov Disord. 2012 Feb;27(2):227-35. doi: 10.1002/mds.23930. Epub 2011 Oct 13.

    PubMed 21997192
  • Doherty KM, Davagnanam I, Molloy S, Silveira-Moriyama L, Lees AJ. Pisa syndrome in Parkinson's disease: a mobile or fixed deformity? J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1400-3. doi: 10.1136/jnnp-2012-304700. Epub 2013 Mar 26.

    PubMed 23532719
  • Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007 Oct 31;22(14):2097-103. doi: 10.1002/mds.21694.

    PubMed 17685467
  • Etoom M, Alwardat M, Aburub AS, Lena F, Fabbrizo R, Modugno N, Centonze D. Therapeutic interventions for Pisa syndrome in idiopathic Parkinson's disease. A Scoping Systematic Review. Clin Neurol Neurosurg. 2020 Nov;198:106242. doi: 10.1016/j.clineuro.2020.106242. Epub 2020 Sep 18.

    PubMed 32979681
  • Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, Morgante F, Fasano A. Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Mov Disord. 2016 Dec;31(12):1785-1795. doi: 10.1002/mds.26829. Epub 2016 Oct 25.

    PubMed 27779784
  • Tassorelli C, De Icco R, Alfonsi E, Bartolo M, Serrao M, Avenali M, De Paoli I, Conte C, Pozzi NG, Bramanti P, Nappi G, Sandrini G. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014 Nov;20(11):1140-4. doi: 10.1016/j.parkreldis.2014.07.015. Epub 2014 Aug 13.

    PubMed 25175601
  • Castrioto A, Piscicelli C, Perennou D, Krack P, Debu B. The pathogenesis of Pisa syndrome in Parkinson's disease. Mov Disord. 2014 Aug;29(9):1100-7. doi: 10.1002/mds.25925. Epub 2014 Jun 7.

    PubMed 24909134
  • Di Matteo A, Fasano A, Squintani G, Ricciardi L, Bovi T, Fiaschi A, Barone P, Tinazzi M. Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms. J Neurol. 2011 May;258(5):740-5. doi: 10.1007/s00415-010-5822-y. Epub 2010 Nov 16.

    PubMed 21079986
  • Tinazzi M, Juergenson I, Squintani G, Vattemi G, Montemezzi S, Censi D, Barone P, Bovi T, Fasano A. Pisa syndrome in Parkinson's disease: an electrophysiological and imaging study. J Neurol. 2013 Aug;260(8):2138-48. doi: 10.1007/s00415-013-6945-8. Epub 2013 May 22.

    PubMed 23695587
  • Bartolo M, Serrao M, Tassorelli C, Don R, Ranavolo A, Draicchio F, Pacchetti C, Buscone S, Perrotta A, Furnari A, Bramanti P, Padua L, Pierelli F, Sandrini G. Four-week trunk-specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease. Mov Disord. 2010 Feb 15;25(3):325-31. doi: 10.1002/mds.23007.

    PubMed 20131386

Questions about this trial

What is this clinical trial studying?

A study testing t-DCS group in people with Parkinson Disease and Pisa Syndrome, run by IRCCS National Neurological Institute "C. Mondino" Foundation at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of Stat Tot (Stat Bend + Stat Flex) (time frame: Change from Baseline at 28 weeks (T2)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04620863, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in